النحاس في الصحة
مراجع

↑  O’Connor، J.M.؛ Bonham، M.P.؛ Turley، E.؛ McKeown، A.؛ McKelvey-Martin، V.J.؛ Gilmore، W.S.؛ Strain، J.J. (2003). "Copper Supplementation Has No Effect on Markers of DNA Damage and Liver Function in Healthy Adults (FOODCUE Project)". Annals of Nutrition and Metabolism. ج. 47 ع. 5: 201–6. DOI:10.1159/000070486. PMID:12748413.
↑  Pratt، William B؛ Omdahl، John L؛ Sorenson، John RJ (1985). "Lack of effects of copper gluconate supplementation". The American Journal of Clinical Nutrition. ج. 42 ع. 4: 681–2. PMID:2931973. مؤرشف من الأصل في 2020-05-12.
↑  Turley، Eithne؛ McKeown، Andrea؛ Bonham، Maxine P.؛ O’Connor، Jacqueline M.؛ Chopra، Mridula؛ Harvey، Linda J.؛ Majsak-Newman، Gosia؛ Fairweather-Tait، Susan J.؛ Bügel، Susanne؛ Sandström، Brittmarie؛ Rock، Edmond؛ Mazur، Andrzej؛ Rayssiguier، Yves؛ Strain، J.J. (2000). "Copper supplementation in humans does not affect the susceptibility of low density lipoprotein to in vitro induced oxidation (FOODCUE project)". Free Radical Biology and Medicine. ج. 29 ع. 11: 1129–34. DOI:10.1016/S0891-5849(00)00409-3. PMID:11121720.
↑  Olivares، Manuel؛ Pizarro، Fernando؛ Speisky، Hernán؛ Lönnerdal، Bo؛ Uauy، Ricardo (1998). "Copper in Infant Nutrition: Safety of World Health Organization Provisional Guideline Value for Copper Content of Drinking Water". Journal of Pediatric Gastroenterology &amp Nutrition. ج. 26 ع. 3: 251–7. DOI:10.1097/00005176-199803000-00003. PMID:9523857.
↑  Milne، David B (1998). "Copper intake and assessment of copper status". The American Journal of Clinical Nutrition. ج. 67 ع. 5 Suppl: 1041S–1045S. PMID:9587149. مؤرشف من الأصل في 2020-05-12.
↑  J. Wang, H. Slunt, V. Gonzales, D. Fromholt, M. Coonfield, N.G. Copeland, N.A. Jenkins, D.R. Borchelt
Copper-binding-site-null SOD1 causes ALS in transgenic mice: aggregates of non-native SOD1 delineate a common feature
Hum. Mol. Genet., 12 (2003), pp. 2753-2764
↑  "CopperInfo.com - Good Health with Copper". مؤرشف من الأصل في 2012-01-01.
1 2 3 4  Kaler، Stephen G. (1998). "Metabolic and molecular bases of Menkes disease and occipital horn syndrome". Pediatric and Developmental Pathology. ج. 1 ع. 1: 85–98. DOI:10.1007/s100249900011. PMID:10463276.
1 2  Kaler، Stephen G. (1996). "Menkes disease mutations and response to early copper histidine treatment". Nature Genetics. ج. 13 ع. 1: 21–2. DOI:10.1038/ng0596-21. PMID:8673098.
↑  Juan M. Pascual*, John H. Menkes†, in Rosenberg's Molecular and Genetic Basis of Neurological and Psychiatric Disease (Fifth Edition), 2015
↑  Kaler، SG (1994). "Menkes disease". Advances in Pediatrics. ج. 41: 263–304. PMID:7992686.
1 2  "نسخة مؤرشفة". مؤرشف من الأصل في 2011-07-08. اطلع عليه بتاريخ 2018-06-07.
↑  Mercer، Julian F B (2001). "The molecular basis of copper-transport diseases". Trends in Molecular Medicine. ج. 7 ع. 2: 64–9. DOI:10.1016/S1471-4914(01)01920-7. PMID:11286757.
↑  Gitlin، Jonathan D (2003). "Wilson disease". Gastroenterology. ج. 125 ع. 6: 1868–77. DOI:10.1053/j.gastro.2003.05.010. PMID:14724838.
↑  Scheinberg، I Herbert؛ Sternlieb، Irmin (1996). "Wilson disease and idiopathic copper toxicosis". The American Journal of Clinical Nutrition. ج. 63 ع. 5: 842S–5S. PMID:8615372. مؤرشف من الأصل في 2020-05-12.
↑  Frommer DJ. Defective biliary excretion of copper in
Wilson’s disease. Gut 1974;15:125–129
1 2  Ferenci، Peter؛ Caca، Karel؛ Loudianos، Georgios؛ Mieli-Vergani، Georgina؛ Tanner، Stuart؛ Sternlieb، Irmin؛ Schilsky، Michael؛ Cox، Diane؛ Berr، Frieder (2003). "Diagnosis and phenotypic classification of Wilson disease". Liver International. ج. 23 ع. 3: 139–42. DOI:10.1034/j.1600-0676.2003.00824.x. PMID:12955875.
↑  Brewer، George J.؛ Dick، Robert D.؛ Johnson، Virginia D.؛ Brunberg، James A.؛ Kluin، Karen J.؛ Fink، John K. (1998). "Treatment of Wilson's disease with zinc: XV long-term follow-up studies". Journal of Laboratory and Clinical Medicine. ج. 132 ع. 4: 264–78. DOI:10.1016/s0022-2143(98)90039-7. PMID:9794697.
↑  Brewer، George J.؛ Johnson، Virginia؛ Dick، Robert D.؛ Kluin، Karen J.؛ Fink، John K.؛ Brunberg، James A. (1996). "Treatment of Wilson Disease With Ammonium Tetrathiomolybdate". Archives of Neurology. ج. 53 ع. 10: 1017–25. DOI:10.1001/archneur.1996.00550100103019. PMID:8859064.
↑  Garciavillarreal، L؛ Daniels، S؛ Shaw، S؛ Cotton، D؛ Galvin، M؛ Geskes، J؛ Bauer، P؛ Sierrahernandez، A؛ Buckler، A؛ Tugores، A (2000). "High prevalence of the very rare wilson disease gene mutation Leu708Pro in the Island of Gran Canaria (Canary Islands, Spain): A genetic and clinical study". Hepatology. ج. 32 ع. 6: 1329–36. DOI:10.1053/jhep.2000.20152. PMID:11093740.
↑  Ha-Hao، Duc؛ Hefter، Harald؛ Stremmel، Wolfgang؛ Castañeda-Guillot، Carlos؛ Hernández، Ana Hernández؛ Cox، Diane W؛ Auburger، Georg (1998). "His1069Gln and six novel Wilson disease mutations: analysis of relevance for early diagnosis and phenotype". European Journal of Human Genetics. ج. 6 ع. 6: 616–23. DOI:10.1038/sj.ejhg.5200237. PMID:9887381.
↑  Wijmenga، C؛ Müller، T؛ Murli، I S؛ Brunt، T؛ Feichtinger، H؛ Schönitzer، D؛ Houwen، R H J؛ Müller، W؛ Sandkuijl، L A؛ Pearson، P L (1998). "Endemic Tyrolean infantile cirrhosis is not an allelic variant of Wilson's disease". European Journal of Human Genetics. ج. 6 ع. 6: 624–8. DOI:10.1038/sj.ejhg.5200235. PMID:9887382.
1 2 3  Müller، Thomas؛ Müller، Wilfried؛ Feichtinger، Hans (1998). "Idiopathic copper toxicosis". The American Journal of Clinical Nutrition. ج. 67 ع. 5 Suppl: 1082S–1086S. PMID:9587156. مؤرشف من الأصل في 2020-05-12.
↑  Dieter، HH؛ Schimmelpfennig، W؛ Meyer، E؛ Tabert، M (1999). "Early childhood cirrhoses (ECC) in Germany between 1982 and 1994 with special consideration of copper etiology". European Journal of Medical Research. ج. 4 ع. 6: 233–42. PMID:10383878.
↑  Goodman، Vicki؛ Brewer، George؛ Merajver، Sofia (2005). "Control of Copper Status for Cancer Therapy". Current Cancer Drug Targets. ج. 5 ع. 7: 543–9. DOI:10.2174/156800905774574066. PMID:16305350.
↑  Gartner، Elaina M.؛ Griffith، Kent A.؛ Pan، Quintin؛ Brewer، George J.؛ Henja، Gwen F.؛ Merajver، Sofia D.؛ Zalupski، Mark M. (2009). "A pilot trial of the anti-angiogenic copper lowering agent tetrathiomolybdate in combination with irinotecan, 5-flurouracil, and leucovorin for metastatic colorectal cancer". Investigational New Drugs. ج. 27 ع. 2: 159–65. DOI:10.1007/s10637-008-9165-9. PMC:4171042. PMID:18712502.
↑  Pass، Harvey I.؛ Brewer، George J.؛ Dick، Robert؛ Carbone، Michele؛ Merajver، Sofia (2008). "A Phase II Trial of Tetrathiomolybdate After Surgery for Malignant Mesothelioma: Final Results". The Annals of Thoracic Surgery. ج. 86 ع. 2: 383–9, discussion 390. DOI:10.1016/j.athoracsur.2008.03.016. PMID:18640301.
↑  Brewer، G. J.؛ Merajver، S. D. (2002). "Cancer Therapy With Tetrathiomolybdate: Antiangiogenesis by Lowering Body Copper—A Review". Integrative Cancer Therapies. ج. 1 ع. 4: 327–37. DOI:10.1177/1534735402238185. PMID:14664727.
↑  Fan، Chuandong؛ Zhao، Jing؛ Zhao، Baoxiang؛ Zhang، Shangli؛ Miao، Junying (2009). "Novel Complex of Copper and a Salicylaldehyde Pyrazole Hydrazone Derivative Induces Apoptosis through Up-Regulating Integrin β4 in Vascular Endothelial Cells". Chemical Research in Toxicology. ج. 22 ع. 9: 1517–25. DOI:10.1021/tx900111y. PMID:19621939.
↑  Brewer، George J. (2001). "Copper Control as an Antiangiogenic Anticancer Therapy: Lessons from Treating Wilson's Disease". Experimental Biology and Medicine. ج. 226 ع. 7: 665–73. PMID:11444102. مؤرشف من الأصل في 12 مايو 2020. اطلع عليه بتاريخ أغسطس 2020. {{استشهاد بدورية محكمة}}: تحقق من التاريخ في: |تاريخ الوصول= (مساعدة)
↑  Lowndes، Sarah A.؛ Harris، Adrian L. (2005). "The Role of Copper in Tumour Angiogenesis". Journal of Mammary Gland Biology and Neoplasia. ج. 10 ع. 4: 299–310. DOI:10.1007/s10911-006-9003-7. PMID:16924372.
↑  Díez، M.؛ Arroyo، M.؛ Cerdàn، F.J.؛ Muñoz، M.؛ Martin، M.A.؛ Balibrea، J.L. (1989). "Serum and Tissue Trace Metal Levels in Lung Cancer". Oncology. ج. 46 ع. 4: 230–4. DOI:10.1159/000226722. PMID:2740065.
↑  Sharma، K؛ Mittal، DK؛ Kesarwani، RC؛ Kamboj، VP؛ Chowdhery (1994). "Diagnostic and prognostic significance of serum and tissue trace elements in breast malignancy". Indian Journal of Medical Sciences. ج. 48 ع. 10: 227–32. PMID:7829172. مؤرشف من الأصل في 2016-02-01.
↑  Daniel، Kenyon G؛ Chen، Di؛ Orlu، Shirley؛ Cui، Qiuzhi؛ Miller، Fred R؛ Dou، Q Ping (2005). "Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells". Breast Cancer Research. ج. 7 ع. 6: R897–908. DOI:10.1186/bcr1322. PMC:1410741. PMID:16280039.{{استشهاد بدورية محكمة}}:  صيانة الاستشهاد: دوي مجاني غير معلم (link)
↑  Chen، Jie؛ Du، Changsheng؛ Kang، Jiuhong؛ Wang، Jianmin (2008). "Cu2+ is required for pyrrolidine dithiocarbamate to inhibit histone acetylation and induce human leukemia cell apoptosis". Chemico-Biological Interactions. ج. 171 ع. 1: 26–36. DOI:10.1016/j.cbi.2007.09.004. PMID:17961528.
1 2  Johnson، David K.؛ Murphy، Terrance B.؛ Rose، Norman J.؛ Goodwin، William H.؛ Pickart، Loren (1982). "Cytotoxic chelators and chelates 1. Inhibition of DNA synthesis in cultured rodent and human cells by aroylhydrazones and by a copper(II) complex of salicylaldehyde benzoyl hydrazone". Inorganica Chimica Acta. ج. 67: 159–65. DOI:10.1016/S0020-1693(00)85058-6.
1 2  Pickart، Loren؛ Goodwin، William H.؛ Burgua، William؛ Murphy، Terrance B.؛ Johnson، David K. (1983). "Inhibition of the growth of cultured cells and an implanted fibrosarcoma by aroylhydrazone analogs of the Gly-His-Lys-Cu (II) complex". Biochemical Pharmacology. ج. 32 ع. 24: 3868–71. DOI:10.1016/0006-2952(83)90164-8. PMID:6661260.
1 2  Ainscough، Eric W؛ Brodie، Andrew M؛ Denny، William A؛ Finlay، Graeme J؛ Gothe، Scott A؛ Ranford، John D (1999). "Cytotoxicity of salicylaldehyde benzoylhydrazone analogs and their transition metal complexes: quantitative structure–activity relationships". Journal of Inorganic Biochemistry. ج. 77 ع. 3–4: 125–33. DOI:10.1016/S0162-0134(99)00131-2. PMID:10643654.
↑  Lu، Yi-Heng؛ Lu، Yu-Wei؛ Wu، Cheng-Li؛ Shao، Qun؛ Chen، Xiao-Ling؛ Bimbong، Rosa Ngo Biboum (2006). "UV–visible spectroscopic study of the salicyladehyde benzoylhydrazone and its cobalt complexes". Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. ج. 65 ع. 3–4: 695–701. Bibcode:2006AcSpA..65..695L. DOI:10.1016/j.saa.2005.12.032. PMID:16503413.
↑  Koh، L.L؛ Kon، O.L؛ Loh، K.W؛ Long، Y.C؛ Ranford، J.D؛ Tan، A.L.C؛ Tjan، Y.Y (1998). "Complexes of salicylaldehyde acylhydrazones: Cytotoxicity, QSAR and crystal structure of the sterically hindered t-butyl dimer". Journal of Inorganic Biochemistry. ج. 72 ع. 3–4: 155–62. DOI:10.1016/S0162-0134(98)10075-2. PMID:10094614.
↑  Xia، Yong؛ Fan، Chuan-Dong؛ Zhao، Bao-Xiang؛ Zhao، Jing؛ Shin، Dong-Soo؛ Miao، Jun-Ying (2008). "Synthesis and structure–activity relationships of novel 1-arylmethyl-3-aryl-1H-pyrazole-5-carbohydrazide hydrazone derivatives as potential agents against A549 lung cancer cells". European Journal of Medicinal Chemistry. ج. 43 ع. 11: 2347–53. DOI:10.1016/j.ejmech.2008.01.021. PMID:18313806.
↑  Fan، ChuanDong؛ Su، Hua؛ Zhao، Jing؛ Zhao، BaoXiang؛ Zhang، ShangLi؛ Miao، JunYing (2010). "A novel copper complex of salicylaldehyde pyrazole hydrazone induces apoptosis through up-regulating integrin β4 in H322 lung carcinoma cells". European Journal of Medicinal Chemistry. ج. 45 ع. 4: 1438–46. DOI:10.1016/j.ejmech.2009.12.048. PMID:20089331.
↑  Winner، Brooke؛ Peipert، Jeffrey F.؛ Zhao، Qiuhong؛ Buckel، Christina؛ Madden، Tessa؛ Allsworth، Jenifer E.؛ Secura، Gina M. (2012). "Effectiveness of Long-Acting Reversible Contraception". New England Journal of Medicine. ج. 366 ع. 21: 1998–2007. DOI:10.1056/NEJMoa1110855. PMID:22621627.
↑  Ortiz، María Elena؛ Croxatto، Horacio B. (يونيو 2007). "Copper-T intrauterine device and levonorgestrel intrauterine system: biological bases of their mechanism of action". Contraception. ج. 75 ع. 6 Suppl: S16‒S30. DOI:10.1016/j.contraception.2007.01.020. PMID:17531610. p. S28:Conclusions
Active substances released from the IUD or IUS, together with products derived from the inflammatory reaction present in the luminal fluids of the genital tract, are toxic for spermatozoa and oocytes, preventing the encounter of healthy gametes and the formation of viable embryos. The current data do not indicate that embryos are formed in IUD users at a rate comparable to that of nonusers. The common belief that the usual mechanism of action of IUDs in women is destruction of embryos in the uterus is not supported by empirical evidence. The bulk of the data indicate that interference with the reproductive process after fertilization has taken place is exceptional in the presence of a T-Cu or LNG-IUD and that the usual mechanism by which they prevent pregnancy in women is by preventing fertilization.
↑  "CopperInfo.com - Plant and Animal Health". مؤرشف من الأصل في 2012-02-18.
بوابة طب
بوابة علم الأحياء
بوابة مطاعم وطعام
أطعمة غنية بالنحاس